8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Jan 12, 2026·SEC
RxSight, Inc.(RXST)Earnings, Financials & Key Ratios
RXST•NASDAQ
$6.78
$280M mkt cap·Price updated May 6, 2026
AboutRxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Show more
- Revenue$134M-3.9%
- EBITDA-$49M-47.4%
- Net Income-$39M-41.8%
- EPS (Diluted)-0.95-33.8%
- Gross Margin76.6%+8.3%
- EBITDA Margin-36.42%-53.3%
- Operating Margin-35.84%-36.0%
- Net Margin-28.96%-47.6%
- ROE-13.99%-12.5%
- ROIC-13.3%-3.5%
- Debt/Equity0.04-8.4%
- Interest Coverage-970.90+25.5%
RXST Key Insights
RxSight, Inc. (RXST) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 55.7%
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RXST Price & Volume
RxSight, Inc. (RXST) stock price & volume — 10-year historical chart
Loading chart...
RXST Growth Metrics
RxSight, Inc. (RXST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years55.74%
3 Years40%
TTM-19.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-75.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-68.66%
Return on Capital
10 Years-32.63%
5 Years-29.23%
3 Years-22.3%
Last Year-16.67%
RXST Recent Earnings
RxSight, Inc. (RXST) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 25, 2026EPS
$0.22
Est $0.33
+34.3%
Revenue
$33M
Est $30M
+8.1%
Q4 2025
Nov 5, 2025EPS
$0.04
Est $0.19
+78.9%
Revenue
$30M
Est $33M
-6.9%
Q3 2025
Aug 7, 2025EPS
$0.08
Est $0.10
+20.0%
Revenue
$34M
Est $26M
+30.6%
Q2 2025
May 7, 2025EPS
$0.03
Est $0.04
+25.0%
Revenue
$38M
Est $38M
-0.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $0.22vs $0.33+34.3% | $33Mvs $30M+8.1% |
| Q4 2025 | Nov 5, 2025 | $0.04vs $0.19+78.9% | $30Mvs $33M-6.9% |
| Q3 2025 | Aug 7, 2025 | $0.08vs $0.10+20.0% | $34Mvs $26M+30.6% |
| Q2 2025 | May 7, 2025 | $0.03vs $0.04+25.0% | $38Mvs $38M-0.0% |
Based on last 12 quarters of dataView full earnings history →
RXST Peer Comparison
RxSight, Inc. (RXST) competitors in Vision, dental, and ENT devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LMAT | 2.51B | 110.22 | 43.74 | 13.53% | 24.35% | 16.19% | 0.47 | |
 ATRC | 1.42B | 28.01 | -116.71 | 14.88% | -0.83% | -0.95% | 0.18 | |
 IRTC | 3.87B | 117.70 | -84.68 | 26.24% | -3.53% | -20.6% | 4.79 | |
 TMDX | 2.52B | 72.92 | 14.97 | 37.13% | 27.04% | 41.92% | 0.99 | |
 ALGN | 12.46B | 173.94 | 30.79 | 0.9% | 10.5% | 10.7% | 0.03 | |
 AHCO | 1.55B | 11.41 | -21.93 | -0.49% | -2.78% | -5.09% | 1.25 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ABT | 149.97B | 86.25 | 11.29 | 4.59% | 31.88% | 27.26% | 0.32 |
Compare RXST vs Peers
RxSight, Inc. (RXST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RXST Income Statement
RxSight, Inc. (RXST) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.24M | 14.68M | 22.59M | 49.01M | 89.08M | 139.93M | 134.48M | 127.48M |
| Revenue Growth % | - | 554.98% | 53.92% | 116.9% | 81.77% | 57.09% | -3.89% | -19.52% |
| Cost of Goods Sold | 4.06M | 12.97M | 18.08M | 27.68M | 35.31M | 40.98M | 31.47M | 29.3M |
| COGS % of Revenue | 181.17% | 88.38% | 80.01% | 56.48% | 39.64% | 29.29% | 23.4% | - |
| Gross Profit | -1.82M▲ 0% | 1.71M▲ 193.7% | 4.52M▲ 164.9% | 21.33M▲ 372.2% | 53.77M▲ 152.1% | 98.94M▲ 84.0% | 103.01M▲ 4.1% | 98.18M▲ 0% |
| Gross Margin % | -81.17% | 11.62% | 19.99% | 43.52% | 60.36% | 70.71% | 76.6% | 77.02% |
| Gross Profit Growth % | - | 193.73% | 164.93% | 372.17% | 152.09% | 84.03% | 4.11% | - |
| Operating Expenses | 44.25M | 37.11M | 57.3M | 84.65M | 103.85M | 135.8M | 151.2M | 153.52M |
| OpEx % of Revenue | 1974.61% | 252.83% | 253.64% | 172.73% | 116.58% | 97.05% | 112.43% | - |
| Selling, General & Admin | 15.2M | 15.18M | 32.8M | 58.66M | 74.8M | 101.43M | 112.65M | 115.87M |
| SG&A % of Revenue | 678.4% | 103.39% | 145.2% | 119.71% | 83.97% | 72.49% | 83.77% | - |
| Research & Development | 29.57M | 21.93M | 24.5M | 25.98M | 29.05M | 34.37M | 38.55M | 37.65M |
| R&D % of Revenue | 1319.46% | 149.43% | 108.44% | 53.02% | 32.61% | 24.56% | 28.67% | - |
| Other Operating Expenses | -521K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -46.07M▲ 0% | -35.41M▲ 23.1% | -52.79M▼ 49.1% | -63.32M▼ 19.9% | -50.09M▲ 20.9% | -36.86M▲ 26.4% | -48.19M▼ 30.7% | -55.35M▲ 0% |
| Operating Margin % | -2055.78% | -241.21% | -233.64% | -129.21% | -56.23% | -26.34% | -35.84% | -43.42% |
| Operating Income Growth % | - | 23.15% | -49.09% | -19.95% | 20.9% | 26.41% | -30.75% | - |
| EBITDA | -42.14M | -31.39M | -48.8M | -59.3M | -45.84M | -33.23M | -48.98M | -56.92M |
| EBITDA Margin % | -1880.41% | -213.88% | -215.99% | -121% | -51.46% | -23.75% | -36.42% | -44.65% |
| EBITDA Growth % | - | 25.5% | -55.45% | -21.51% | 22.69% | 27.5% | -47.36% | -69.43% |
| D&A (Non-Cash Add-back) | 3.93M | 4.01M | 3.99M | 4.02M | 4.24M | 3.62M | -785K | -1.57M |
| EBIT | 126.27M | 28.14M | -45M | -61.8M | -45.28M | -27.38M | -38.84M | -30.69M |
| Net Interest Income | 2.28M | 33K | -3.63M | -3.43M | 3.27M | 9.45M | 2.47M | 2.24M |
| Interest Income | 2.31M | 543K | 54K | 1.52M | 6.57M | 9.47M | 2.51M | 2.25M |
| Interest Expense | 26K | 510K | 3.68M | 4.95M | 3.31M | 21K | 40K | 10K |
| Other Income/Expense | 172.31M | 63.04M | 4.11M | -3.43M | 1.5M | 9.45M | 9.31M | 8.76M |
| Pretax Income | 126.24M▲ 0% | 27.63M▼ 78.1% | -48.68M▼ 276.2% | -66.75M▼ 37.1% | -48.59M▲ 27.2% | -27.41M▲ 43.6% | -38.88M▼ 41.9% | -46.58M▲ 0% |
| Pretax Margin % | 5633.38% | 188.25% | -215.47% | -136.2% | -54.55% | -19.59% | -28.91% | -36.54% |
| Income Tax | 24K | 57K | 8K | 9K | 20K | 50K | 66K | 54K |
| Effective Tax Rate % | 0.02% | 0.21% | -0.02% | -0.01% | -0.04% | -0.18% | -0.17% | -0.12% |
| Net Income | 126.22M▲ 0% | 27.57M▼ 78.2% | -48.69M▼ 276.6% | -66.76M▼ 37.1% | -48.61M▲ 27.2% | -27.45M▲ 43.5% | -38.94M▼ 41.8% | -46.64M▲ 0% |
| Net Margin % | 5632.31% | 187.87% | -215.5% | -136.22% | -54.57% | -19.62% | -28.96% | -36.58% |
| Net Income Growth % | - | -78.15% | -276.57% | -37.11% | 27.19% | 43.52% | -41.84% | -75.69% |
| Net Income (Continuing) | 126.22M | 27.57M | -48.69M | -66.76M | -48.61M | -27.45M | -38.94M | -46.64M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 6.62▲ 0% | 0.18▼ 97.3% | -1.78▼ 1088.9% | -2.41▼ 35.4% | -1.41▲ 41.5% | -0.71▲ 49.6% | -0.95▼ 33.8% | -1.13▲ 0% |
| EPS Growth % | - | -97.28% | -1088.89% | -35.39% | 41.49% | 49.65% | -33.8% | -68.66% |
| EPS (Basic) | 0.95 | 0.18 | -1.78 | -2.41 | -1.41 | -0.71 | -0.95 | - |
| Diluted Shares Outstanding | 19.07M | 19.07M | 27.37M | 27.66M | 34.46M | 38.87M | 41.18M | 41.31M |
| Basic Shares Outstanding | 19.07M | 19.07M | 27.37M | 27.66M | 34.46M | 38.87M | 41.18M | 41.31M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
RXST Balance Sheet
RxSight, Inc. (RXST) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 90.2M | 81.5M | 176.29M | 134.56M | 168.41M | 293.82M | 287.46M | 279.23M |
| Cash & Short-Term Investments | 80.67M | 68.97M | 159.33M | 105.8M | 127.18M | 237.22M | 228.13M | 217.88M |
| Cash Only | 7.96M | 13.99M | 24.36M | 11.83M | 9.69M | 16.71M | 19.95M | 17.57M |
| Short-Term Investments | 72.71M | 54.98M | 134.97M | 93.97M | 117.49M | 220.52M | 208.18M | 200.31M |
| Accounts Receivable | 789K | 2.87M | 4.86M | 10.96M | 20.28M | 30.05M | 23.38M | 22.44M |
| Days Sales Outstanding | 128.51 | 71.24 | 78.55 | 81.6 | 83.1 | 78.39 | 63.47 | 70.17 |
| Inventory | 7.22M | 8.29M | 8.03M | 14.84M | 17.42M | 22.01M | 31.56M | 34.87M |
| Days Inventory Outstanding | 649 | 233.19 | 162.19 | 195.64 | 180.07 | 196.01 | 366.04 | 375.1 |
| Other Current Assets | 0 | 0 | 0 | 2.96M | 3.52M | 4.54M | 4.39M | 4.03M |
| Total Non-Current Assets | 20.23M | 19.18M | 16.43M | 15.61M | 14.14M | 24.74M | 24.36M | 24.77M |
| Property, Plant & Equipment | 19.25M | 18.61M | 15.5M | 14.08M | 13.29M | 23.63M | 23.02M | 22.99M |
| Fixed Asset Turnover | 0.12x | 0.79x | 1.46x | 3.48x | 6.71x | 5.92x | 5.84x | 5.47x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 711K | 750K | 0 | 1.5M |
| Other Non-Current Assets | 983K | 571K | 925K | 1.53M | 147K | 360K | 1.34M | 4.19M |
| Total Assets | 110.43M▲ 0% | 100.68M▼ 8.8% | 192.72M▲ 91.4% | 150.16M▼ 22.1% | 182.55M▲ 21.6% | 318.56M▲ 74.5% | 311.81M▼ 2.1% | 303.99M▲ 0% |
| Asset Turnover | 0.02x | 0.15x | 0.12x | 0.33x | 0.49x | 0.44x | 0.43x | 0.41x |
| Asset Growth % | - | -8.83% | 91.43% | -22.08% | 21.57% | 74.51% | -2.12% | -4.48% |
| Total Current Liabilities | 8.46M | 11.6M | 11.08M | 17.24M | 20.9M | 25.88M | 26.25M | 27.38M |
| Accounts Payable | 2.2M | 1.13M | 1.69M | 2.6M | 3.86M | 4.54M | 5.3M | 7.12M |
| Days Payables Outstanding | 197.69 | 31.91 | 34.11 | 34.22 | 39.93 | 40.47 | 61.43 | 59.63 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 1.16M | 1.5M |
| Deferred Revenue (Current) | 378K | 417K | 618K | 1.35M | 2.04M | 3.11M | 0 | 0 |
| Other Current Liabilities | 4.89M | 8.78M | 6.92M | 10.87M | 2.56M | 17.25M | 19.8M | 25.87M |
| Current Ratio | 10.67x | 7.03x | 15.92x | 7.81x | 8.06x | 11.36x | 10.95x | 10.95x |
| Quick Ratio | 9.81x | 6.31x | 15.19x | 6.95x | 7.22x | 10.50x | 9.75x | 9.75x |
| Cash Conversion Cycle | 579.81 | 272.52 | 206.63 | 243.02 | 223.24 | 233.93 | 368.08 | 385.65 |
| Total Non-Current Liabilities | 406.59M | 386.61M | 43.4M | 43.02M | 1.28M | 11.45M | 9.88M | 9.32M |
| Long-Term Debt | 0 | 24.4M | 39.76M | 40.17M | 0 | 0 | 9.88M | 9.32M |
| Capital Lease Obligations | 4.53M | 5.08M | 3.64M | 2.86M | 1.21M | 11.32M | 0 | 20.89M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 402.06M | 357.13M | 0 | 0 | 74K | 127K | 0 | 0 |
| Total Liabilities | 415.04M | 398.21M | 54.48M | 60.26M | 22.19M | 37.33M | 36.13M | 36.7M |
| Total Debt | 5.52M | 30.75M | 44.93M | 44.99M | 3.01M | 12.3M | 11.04M | 10.83M |
| Net Debt | -2.44M | 16.76M | 20.57M | 33.16M | -6.68M | -4.41M | -8.91M | -6.75M |
| Debt / Equity | - | - | 0.33x | 0.50x | 0.02x | 0.04x | 0.04x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.19x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.12x |
| Interest Coverage | 4856.54x | 55.18x | -12.22x | -12.50x | -13.69x | -1304.00x | -970.90x | -3069.20x |
| Total Equity | -304.61M▲ 0% | -297.53M▲ 2.3% | 138.24M▲ 146.5% | 89.9M▼ 35.0% | 160.36M▲ 78.4% | 281.24M▲ 75.4% | 275.68M▼ 2.0% | 267.3M▲ 0% |
| Equity Growth % | - | 2.32% | 146.46% | -34.97% | 78.37% | 75.38% | -1.98% | -5.73% |
| Book Value per Share | -15.97 | -15.60 | 5.05 | 3.25 | 4.65 | 7.24 | 6.70 | 6.47 |
| Total Shareholders' Equity | -304.61M | -297.53M | 138.24M | 89.9M | 160.36M | 281.24M | 275.68M | 267.3M |
| Common Stock | 56.42M | 80.78M | 27K | 28K | 36K | 40K | 41K | 41K |
| Retained Earnings | -419.86M | -430.59M | -479.28M | -546.03M | -594.64M | -622.1M | -661.04M | -676.92M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 46K | -3K | -20K | -95K | -5K | 166K | 53K | -67K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RXST Cash Flow Statement
RxSight, Inc. (RXST) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -40.62M | -35.2M | -44.71M | -58.85M | -41.59M | -16.95M | -15.51M | -15.51M |
| Operating CF Margin % | -1812.54% | -239.84% | -197.88% | -120.09% | -46.69% | -12.11% | -11.53% | - |
| Operating CF Growth % | - | 13.33% | -27% | -31.63% | 29.32% | 59.26% | 8.47% | -218.66% |
| Net Income | 126.22M | 27.57M | -48.69M | -66.76M | -48.61M | -27.45M | 0 | -46.64M |
| Depreciation & Amortization | 3.93M | 4.01M | 3.99M | 4.02M | 4.24M | 3.62M | 0 | 49K |
| Stock-Based Compensation | 4.6M | 4.18M | 7.58M | 11.4M | 15.75M | 24.64M | 0 | 805K |
| Deferred Taxes | 0 | -63.21M | -5.4M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -171.4M | 85K | 493K | -101K | -3.9M | -8.54M | -10.62M | -12.05M |
| Working Capital Changes | -3.97M | -7.85M | -2.68M | -7.41M | -9.07M | -9.21M | -4.89M | 1.32M |
| Change in Receivables | -789K | -2.08M | -2M | -6.09M | -9.32M | -9.8M | 6.66M | 8.52M |
| Change in Inventory | -5.47M | -1.31M | -2.11M | -7.55M | -2.75M | -4.99M | -11.48M | -13.26M |
| Change in Payables | 1.13M | -954K | 555K | 635K | 1.25M | 946K | 627K | -22K |
| Cash from Investing | -5.87M | 15.59M | -81.91M | 39.95M | -22.13M | -99.31M | 16.89M | 4.88M |
| Capital Expenditures | -4.09M | -2.54M | -1.94M | -2.39M | -4.81M | -5.44M | -3.83M | -184K |
| CapEx % of Revenue | 182.33% | 17.3% | 8.59% | 4.88% | 5.4% | 3.89% | 2.85% | - |
| Acquisitions | 603K | 3K | 79.97M | -42.34M | 17.32M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -79.97M | 42.34M | -17.32M | 0 | 0 | 16.89M |
| Cash from Financing | 1.33M | 25.24M | 137.34M | 6.33M | 61.52M | 123.32M | 1.86M | 2.26M |
| Debt Issued (Net) | -185K | 24.86M | 14.97M | -121K | -40.15M | -61K | -26K | -13K |
| Equity Issued (Net) | 0 | 1.01M | 121.14M | 7.83M | 105.96M | 128.92M | 3.95M | 3.25M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.51M | -636K | 1.23M | -1.38M | -4.28M | -5.54M | -2.06M | -980K |
| Net Change in Cash | -45.15M▲ 0% | 5.63M▲ 112.5% | 10.72M▲ 90.5% | -12.58M▼ 217.4% | -2.19M▲ 82.6% | 7.05M▲ 421.8% | 3.24M▼ 54.0% | -10.43M▲ 0% |
| Free Cash Flow | -44.7M▲ 0% | -37.74M▲ 15.6% | -46.65M▼ 23.6% | -61.24M▼ 31.3% | -46.41M▲ 24.2% | -22.39M▲ 51.8% | -19.34M▲ 13.6% | -2.24M▲ 0% |
| FCF Margin % | -1994.87% | -257.13% | -206.47% | -124.97% | -52.1% | -16% | -14.38% | -1.76% |
| FCF Growth % | - | 15.58% | -23.6% | -31.29% | 24.22% | 51.76% | 13.6% | 89.07% |
| FCF per Share | -2.34 | -1.98 | -1.70 | -2.21 | -1.35 | -0.58 | -0.47 | -0.47 |
| FCF Conversion (FCF/Net Income) | -0.32x | -1.28x | 0.92x | 0.88x | 0.86x | 0.62x | 0.40x | 0.05x |
| Interest Paid | 26K | 425K | 3.19M | 4.26M | 3.48M | 21K | 0 | 0 |
| Taxes Paid | 19K | 61K | 20K | 3K | 8K | 24K | 58K | 55K |
RXST Key Ratios
RxSight, Inc. (RXST) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -35.22% | -58.52% | -38.85% | -12.43% | -13.99% | -17.01% |
| Return on Invested Capital (ROIC) | - | -24.93% | -33.69% | -27.15% | -12.84% | -13.3% | -13.3% |
| Gross Margin | 11.62% | 19.99% | 43.52% | 60.36% | 70.71% | 76.6% | 77.02% |
| Net Margin | 187.87% | -215.5% | -136.22% | -54.57% | -19.62% | -28.96% | -36.58% |
| Debt / Equity | - | 0.33x | 0.50x | 0.02x | 0.04x | 0.04x | 0.04x |
| Interest Coverage | 55.18x | -12.22x | -12.50x | -13.69x | -1304.00x | -970.90x | -3069.20x |
| FCF Conversion | -1.28x | 0.92x | 0.88x | 0.86x | 0.62x | 0.40x | 0.05x |
| Revenue Growth | 554.98% | 53.92% | 116.9% | 81.77% | 57.09% | -3.89% | -19.52% |
RXST SEC Filings & Documents
RxSight, Inc. (RXST) SEC filings — annual & quarterly reports (10-K, 10-Q)
RXST Frequently Asked Questions
RxSight, Inc. (RXST) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
RxSight, Inc. (RXST) reported $127.5M in revenue for fiscal year 2025. This represents a 5588% increase from $2.2M in 2019.
RxSight, Inc. (RXST) saw revenue decline by 3.9% over the past year.
RxSight, Inc. (RXST) reported a net loss of $46.6M for fiscal year 2025.
Dividend & Returns
RxSight, Inc. (RXST) has a return on equity (ROE) of -14.0%. Negative ROE indicates the company is unprofitable.
RxSight, Inc. (RXST) had negative free cash flow of $2.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More RXST
RxSight, Inc. (RXST) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates